Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®) An open label, uncontrolled study

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 2, 2014, Pages 441-448

  Vinnemeier, Christof David ^a,b   Fischer Herr, Johanna ^a,b   Meyer, Seetha ^c   Liebig, Katja ^c   Theeß, Wiebke ^b   Burchard, Gerd Dieter ^a,b   Cramer, Jakob P ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c Novartis Vaccines and Diagnostics GmbH   (Germany)

Author keywords

H1N1; H3N2; Influenza; Optaflu; Pandemic; Trivalent vaccine

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CARPAL TUNNEL SYNDROME; CELL CULTURE; CHILL; CLINICAL TRIAL; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ECCHYMOSIS; EYE INFLAMMATION; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALE; MAMMAL CELL; MYALGIA; NONHUMAN; OPEN STUDY; SEASONAL INFLUENZA; SEROCONVERSION; SHIVERING; SINGLE DRUG DOSE; SWEATING; ADOLESCENT; BLOOD; CULTURE TECHNIQUE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INFLUENZA, HUMAN; MIDDLE AGED; PAIN; PATHOLOGY; PHARMACEUTICS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CELL CULTURE TECHNIQUES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MYALGIA; PAIN; TECHNOLOGY, PHARMACEUTICAL; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84896907539     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27140     Document Type: Article

References (48)

1. World Health Organization. (2009) Influenza (seasonal) Available: http://www.who.int/mediacentre/ factsheets/fs211/en/index.html Accessed: 06.12.2012
2. Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, Bridges CB, Grijalva CG, Zhu Y, Bernstein DI, et al.; New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N Engl J Med 2006; 355:31-40; PMID:16822994; http://dx.doi.org/10.1056/ NEJMoa054869
3. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NS; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57(RR-7):1-60; PMID:18685555
4. Center for Disease Control and Prevention (CDC). (2012) Update: Influenza Activity -United States, 2011-12 Season and Composition of the 2012-13 Influenza Vaccine Available: http://www.cdc. gov/mmwr/preview/mmwrhtml /mm6122a4.htm Accessed: 06.12.2012.
5. Center for Disease Control and Prevention (CDC). (2012) Flu Symptoms and Severity Available: http:// www.cdc.gov/f lu/about/disease /symptoms.htm Accessed: 06.12.2012
6. Chen J, Deng YM. Influenza virus antigenic variation, host antibody production and new approach to control epidemics. Virol J 2009; 6:30; PMID:19284639; http://dx.doi.org/10.1186/1743-422X-6-30
7. Cramer J, Mac T, Hogan B, Stauga S, Eberhardt S, Wichmann O, Mertens T, Burchard G. Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany. Euro Surveill 2012; 17:17; PMID:22264864
8. Pebody R, Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, Thomas D, Sebastianpillai P, Ellis J, Carman W, et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Euro Surveill 2011; 16:16; PMID:21329644
9. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, Lilac HA, Hall H, Klimov A, Fukuda K. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284:1655-63; PMID:11015795; http://dx.doi.org/10.1001/ jama.284.13.1655
10. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997-1004; PMID:20868284; http://dx.doi.org/10.1086/656578
11. Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009; 8:679-88; PMID:19485748; http://dx.doi.org/10.1586/ erv.09.31
12. Stöhr K. Vaccinate before the next pandemic? Nature 2010; 465:161; PMID:20463719; http://dx.doi. org/10.1038/465161a
13. Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol 2006; 24:1377-83; PMID:17093488; http://dx.doi. org/10.1038/nbt1261 (Pubitemid 44722101)
14. World Health Organization. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull World Health Organ 1995; 73:431-5; PMID:7554013
15. Wright PF. Vaccine preparedness-are we ready for the next influenza pandemic? N Engl J Med 2008; 358:2540-3; PMID:18550873; http://dx.doi. org/10.1056/NEJMp0803650 (Pubitemid 351831355)
16. Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine 2009; 27:6022-9; PMID:19666152; http://dx.doi.org/10.1016/j.vaccine.2009.07.083
17. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841-8; PMID:19673651; http://dx.doi.org/10.1086/605505
18. European Medicines Agency. (2008) Optaflu Available: http://www.ema. europa.eu/ema/ i nde x . j sp ? cur l = pa g e s /med i c i n e s /huma n / medic ine s / 0 0 0758 /humanmed 0 0 0952. jsp&mid=WC0b01ac058001d124 Accessed: 06.12.2012
19. Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J 2012; 31:494-500; PMID:22301476; http://dx.doi.org/10.1097/ INF.0b013e31824bb179
20. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 2009; 27:786-91; PMID:19027046; http:// dx.doi.org/10.1016/j.vaccine.2008.11.003
21. World Health Organization. (2012) Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season Available: http://www.who.int/influenza/vaccines/virus/recommendations/ 201202recommendation. pdf Accessed: 08.12.2012.
22. Loebermann M, Anders G, Brestrich G, Fritzsche C, Klammt S, Boršo D, Frimmel S, Riebold D, Reisinger EC. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study. Vaccine 2011; 29:1228-34; PMID:21167116; http://dx.doi. org/10.1016/j.vaccine.2010.11. 092
23. Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination. PLoS One 2013; 8:e70866; PMID:23976960; http://dx.doi.org/10.1371/journal.pone.0070866
24. Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G. A randomised, singleblind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. Vaccine 2012; 30:4820-7; PMID:22626675; http:// dx.doi.org/10.1016/j.vaccine. 2012.05.013
25. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35; PMID:19745215; http://dx.doi.org/10. 1056/ NEJMoa0907650
26. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69; PMID:16213065; http://dx.doi.org/10.1016/j. vaccine.2005.08.105 (Pubitemid 43202262)
27. Bateman AC, Kieke BA, Irving SA, Meece JK, Shay DK, Belongia EA. Effectiveness of Monovalent A(H1N1)pdm09 and 2010-11 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-11 Season. J Infect Dis 2013
28. Lessler J, Riley S, Read JM, Wang S, Zhu H, Smith GJ, Guan Y, Jiang CQ, Cummings DA. Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China. PLoS Pathog 2012; 8:e1002802; PMID:22829765; http://dx.doi. org/10.1371/journal.ppat.1002802
29. Iorio AM, Bistoni O, Galdiero M, Lepri E, Camilloni B, Russano AM, Neri M, Basileo M, Spinozzi F. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. Vaccine 2012; 30:1617-23; PMID:22245606; http://dx.doi.org/10.1016/j. vaccine.2011.12.107
30. Luytjes W, Enouf V, Schipper M, Gijzen K, Liu WM, van der Lubben M, Meijer A, van der Werf S, Soethout EC. HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains. Vaccine 2012; 30:5262-9; PMID:22691431; http://dx.doi.org/10.1016/j.vaccine.2012.05.060
31. Hayden F, Palese P. (2009) Influenza virus. In: Richman D, Whitley R, Hayden F, editors, editors. Clinical Virology: ASM press. pp. 943-976.
32. International Society for Infectious Diseases. (2013) PROMED -Influenza (18): European region update 08 Feb 2013 Available: http://www.promedmail.org/ Accessed: 08.02.2013.
33. Campbell JD, Chambers CV, Brady RC, Caldwell MC, Bennett NL, Fourneau MA, Jain VK, Innis BL. Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adults. Hum Vaccin 2011; 7:81-8; PMID:21285532; http:// dx.doi.org/10.4161/ hv.7.1.13553
34. Song JY, Cheong HJ, Woo HJ, Wie SH, Lee JS, Chung MH, Kim YR, Jung SI, Park KH, Kim TH, et al. Immunogenicity and safety of trivalent inactivated influenza vaccine: a randomized, doubleblind, multi-center, phase 3 clinical trial in a vaccinelimited country. J Korean Med Sci 2011; 26:191-5; PMID:21286008; http://dx.doi.org/10.3346/ jkms.2011.26.2.191
35. Allwinn R, Bickel M, Lassmann C, Wicker S, Friedrichs I. "Trivalent influenza vaccination of healthy adults 3 years after the onset of swineorigin H1N1 pandemic: restricted immunogenicity of the new A/H1N1v constituent?". Med Microbiol Immunol 2013; 202:125-30; PMID:22986732
36. Kulkarni PS, Manjunath K, Agarkhedkar S; Group of SII IIV Studies. Safety and immunogenicity of an adjuvanted whole virion, inactivated A (H1N1) 2009 influenza vaccine in young and elderly adults, and children. Vaccine 2012; 31:20-2; PMID:23131207; http://dx.doi.org/10.1016/j.vaccine.2012.10.081
37. Böhmer MM, Walter D, Falkenhorst G, Müters S, Krause G, Wichmann O. Barriers to pandemic influenza vaccination and uptake of seasonal influenza vaccine in the post-pandemic season in Germany. BMC Public Health 2012; 12:938; PMID:23113995; http://dx.doi.org/10.1186/1471-2458-12-938
38. Robert Koch Institut (RKI). (2013) Infektionsschutz -Wie viele Menschen lassen sich gegen die saisonale Influenza impfen? Available: http://www.rki.de/ SharedDocs/FAQ/Impfen/Inf luenza/FAQ06.html Accessed: 19.10.2013.
39. Brydak LB, Tadeusz S, Magdalena M. Antibody response to influenza vaccination in healthy adults. Viral Immunol 2004; 17:609-15; PMID:15671759; http://dx.doi.org/10.1089/vim.2004.17.609 (Pubitemid 40063602)
40. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009; 200:849-57; PMID:19673652; http:// dx.doi.org/10.1086/605506
41. Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respi Viruses 2012 6: 142-152, e141-145.
42. EU Clinical Trials Register. (2012) A Phase III Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu®), Formulation 2012/2013, when Administered to adult and elderly subjects. Available: https://www.clinicaltrialsregister. eu/ctr-search/trial/ 2011-006277-25/DE Accessed: 02.02.2013.
43. ClinicalTrials.gov. (2012) Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above Available: http://clinicaltrials.gov/ct2/show/ NCT01640314?term= NCT01640314&rank=1 Accessed: 21.12. 2012.
44. Keitel WA, Couch RB, Cate TR, Hess KR, Baxter B, Quarles JM, Atmar RL, Six HR. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 1994; 32:2468-73; PMID:7814484 (Pubitemid 24284647)
45. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutinationinhibiting antibody to influenza virus. Dev Biol (Basel) 2003; 115:63-73; PMID:15088777
46. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:69-75; PMID:367490
47. The Committee for Proprietary Medicinal Products (CHMP). (2009) Note for guidance on harmonisation of requirements for influenza vaccines. CHMP/BWP/214/96. Available: http://www. ema.europa.eu/docs /enGB/ documentlibrary/ Scientificguideline/2009/09/WC500003945.pdf Accessed: 29.11.2012.
48. Brighton Collaboration. (2012) Vaccine Safety Research Standards Available: https:// brightoncollaboration.org/public Accessed: 07.12.2012.